Biotech API manufacturing services market to reach $5.78bn in 2019, according to Visiongain

 
 
vg
vg
LONDON - Sept. 17, 2015 - PRLog -- Press release text for Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025 – Contract Manufacturing Organisations (CSOs) Serving Biopharma

Biotech API manufacturing services market to reach $5.78bn in 2019, according to new visiongain data

A new report by visiongain forecasts the overall world biotech API manufacturing services industry will achieve revenues of $5.78 billion in 2019. That sales prediction and others appear in Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025 – Contract Manufacturing Organisations (CSOs) Serving Biopharma, published in July 2015.

That survey analyses events, prospects and sales opportunities shaping those production services for biological drugs (biologics). The work shows multilevel revenue forecasting and qualitative analyses. It also assesses activities of leading contract manufacturing organisations (CMOs). Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand industries and markets, especially their commercial prospects.

Biotech API (active pharmaceutical ingredient) production involves supplying medicinal components needed in biological drugs. Visiongain’s study predicts the biotech API manufacturing services industry will expand in revenue at a CAGR of 8.3% from 2014 to 2025. That market holds strong growth potential, serving important needs in the biologics industry, as well as the emerging biosimilars field. In 2014, the mammalian cell culture submarket formed the most lucrative part of that industry, accounting for 63.98% of the overall world market. The study shows that segment will achieve strong revenue expansion from 2015 to 2025.

Mashael Zaidi, a pharmaceutical industry analyst in visiongain, said: “Biotech API manufacturing services will be in more demand as outsourcing is set to increase in the coming 10 years. The main drivers for this demand will be the increased interest in the biologics market and the biosimilars market. As original branded drugs come off patent, companies will vie to produce biosimilars and new biologics. This will result in more demand for biotech API production and drive growth of that market.

“Outsourcing API manufacturing services for biologics to CMOs provides benefits to pharmaceutical companies and specialist drug developers and producers. Big Pharma will be increasingly looking to cut costs. This is in addition to smaller pharma companies who outsource to access expertise and gain entry to markets that they otherwise would not be able to reach. The future will also hold many partnerships, as CMOs and biological drug companies turn to each other for alliances that provide capacity, technology and expertise. Partnerships make use of each side’s strengths and lessen risks such as overcapacity.

“The leading biological drugs market in the next 10 years will be the monoclonal antibody therapies market, and CMOs will gain much of their revenue from that segment. Monoclonal antibodies (mAbs) provide much opportunity owing to their extensive R&D. Also the success of existing biologic blockbusters will result in many companies from 2015 to 2025 attempting to achieve blockbuster sales. Many of those firms will rely on contract API manufacturers to provide the production means.

“Our analysis shows the biotech API manufacturing services market will achieve high revenue growth over the forecast period to 2025. Interest in that field grows, as it is cost saving to outsource compared with building new facilities or investing in biotechnologies.”

Visiongain’s new investigation shows biotech API manufacturing revenue forecasts to 2025 at world market, submarket and national level.

It forecasts the following subsectors of biotech API manufacturing services to 2025:

·         Mammalian cell cultures

·         Microbial fermentation processes

·         Other expression systems for drug making.

That study also breaks its overall world revenue forecast to 2025 into these therapeutic classes, for API revenues:

·         Monoclonal antibodies (mAbs)

·         Insulin

·         Vaccines

·         Interferons

·         Human growth hormones.

The work also analyses leading national markets for biological API services, providing revenue forecasts to 2025 for these countries:

·         United States (US)

·         Germany, France, UK, Italy, Spain (EU5 group) and Switzerland

·         Japan

·         Brazil, Russia, India and China (BRIC nations)

·         South Korea

·         Singapore.

That survey examines leading CMOs and CMO divisions of biopharma companies. The investigation also discusses facilities, capacity, expansions, mergers and acquisitions involved with CMOs. Companies the report profiles include these organisations:

·         Boehringer Ingelheim BioXcellence

·         Celltrion

·         DSM Biologics

·         Lonza

·         Samsung BioLogics

·         FUJIFILM Diosynth Biotechnologies.

Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025 adds to visiongain’s range of reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).

Contact
Sara Peerun
***@visiongainglobal.com
End
Source: » Follow
Email:***@visiongainglobal.com Email Verified
Tags:Biological, Pharma, Drug
Industry:Business
Location:London City - London, Greater - England
Subject:Reports
Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share